Foghorn Therapeutics (FHTX) Return on Sales (2020 - 2026)

Foghorn Therapeutics' Return on Sales history runs 7 years deep, the most recent figure standing at 0.25% for Q1 2026.

• On a quarterly basis, Return on Sales fell 21.0% year-over-year to 0.25% in Q1 2026; TTM through Mar 2026 was 0.08%, a 4.0% decrease from a year earlier, with the FY2025 full-year figure at 0.09%, down 5.0% from the prior year.
• Return on Sales eased to 0.25% in Q1 2026 per FHTX's latest filing, from 0.03% in the prior quarter.
• Across five years, Return on Sales topped out at 0.01% in Q3 2023 and bottomed at 0.25% in Q1 2026.
• The 5-year median for Return on Sales is 0.05% (2025), against an average of 0.06%.
• Across the five-year window, Return on Sales surged 2443 bps in 2022 and declined 21 bps in 2026, its largest moves.
• Year by year, Return on Sales stood at 0.07% in 2022, then soared by 39 bps to 0.04% in 2023, then plunged by 63 bps to 0.07% in 2024, then jumped by 62 bps to 0.03% in 2025, then tumbled by 857 bps to 0.25% in 2026.
• Per Business Quant, the three latest FHTX Return on Sales figures stand at 0.25% (Q1 2026), 0.03% (Q4 2025), and 0.05% (Q3 2025).